US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
US7070782B1
(en)
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
US6569432B1
(en)
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
US7037647B1
(en)
|
1995-02-24 |
2006-05-02 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
US6150508A
(en)
*
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6207805B1
(en)
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
GB2328871A
(en)
*
|
1997-09-05 |
1999-03-10 |
Merck & Co Inc |
Compositions for inhibiting platelet aggregation
|
WO1999043710A1
(en)
*
|
1998-02-26 |
1999-09-02 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
EP2080802B1
(en)
*
|
1998-06-01 |
2017-03-29 |
Agensys, Inc. |
Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
SE9900495D0
(sv)
*
|
1999-02-12 |
1999-02-12 |
Pharmatrix Ab |
Vaccine composition
|
WO2000050457A1
(en)
*
|
1999-02-22 |
2000-08-31 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
EP1210374B1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
FR2797743B1
(fr)
*
|
1999-08-23 |
2003-08-08 |
Urogene |
Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
|
WO2001019956A2
(en)
*
|
1999-09-13 |
2001-03-22 |
Bander Neil H |
A method for isolation of prostatic epithelial cells from semen
|
JP4838436B2
(ja)
*
|
2001-04-04 |
2011-12-14 |
積水メディカル株式会社 |
抗ヒト肝性トリグリセリドリパーゼ抗体
|
EP2277542B1
(en)
|
2001-06-01 |
2014-04-16 |
Cornell Research Foundation Inc. |
Modified antibodies to prostrate-specific membrane antigen and uses thereof
|
AU2002305767B2
(en)
|
2001-09-20 |
2008-04-10 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
|
AU2002356844C1
(en)
|
2001-10-23 |
2010-03-04 |
Amgen Fremont Inc. |
PSMA antibodies and protein multimers
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
US20040161776A1
(en)
*
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
ATE408712T1
(de)
|
2003-01-10 |
2008-10-15 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
EP1851251A2
(en)
|
2005-02-18 |
2007-11-07 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
JP2009509510A
(ja)
|
2005-09-26 |
2009-03-12 |
メダレックス インコーポレーティッド |
Cd70に対するヒトモノクローナル抗体
|
ES2363891T3
(es)
|
2006-03-20 |
2011-08-18 |
The Regents Of The University Of California |
Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
|
WO2009032949A2
(en)
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
EP2255188B1
(en)
*
|
2008-02-29 |
2016-08-24 |
Imec |
Biosensor for the detection of neurotransmitters
|
DK2326350T3
(da)
|
2008-09-08 |
2013-12-16 |
Psma Dev Company L L C |
Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
WO2011069019A2
(en)
|
2009-12-02 |
2011-06-09 |
David Ho |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
TWI636793B
(zh)
|
2011-04-21 |
2018-10-01 |
西雅圖遺傳學公司 |
新穎結合劑-藥物接合物(ADCs)及其用途(二)
|
CA2833019A1
(en)
|
2011-04-22 |
2012-10-26 |
Emergent Product Development Seattle, Llc |
Prostate-specific membrane antigen binding proteins and related compositions and methods
|
BR112016014830A2
(pt)
|
2013-12-23 |
2017-09-19 |
Bayer Pharma AG |
Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
|
CA2990076A1
(en)
|
2015-06-22 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
KR20180050321A
(ko)
|
2015-08-07 |
2018-05-14 |
이미지냅 인코포레이티드 |
분자를 표적화하기 위한 항원 결합 구조체
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
SG11201808167VA
(en)
|
2016-03-24 |
2018-10-30 |
Bayer Pharma AG |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
US11001636B2
(en)
|
2016-06-15 |
2021-05-11 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
|
IL310558A
(en)
|
2016-12-21 |
2024-03-01 |
Bayer Pharma AG |
Drug-antibody conjugates with enzymatically cleavable groups
|
WO2018114804A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
|
KR20190099250A
(ko)
|
2016-12-21 |
2019-08-26 |
바이엘 악티엔게젤샤프트 |
효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
|
KR20200130709A
(ko)
|
2018-03-06 |
2020-11-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
전립선-특이 막 항원 car 및 이의 사용 방법
|
CA3103936A1
(en)
*
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
HUE061078T2
(hu)
|
2018-07-31 |
2023-05-28 |
Heidelberg Pharma Res Gmbh |
PSMA elleni humanizált ellenanyagok
|